| Are at-risk New Zealand women receiving recommended cardiovascular preventive therapy? | |
| | |
MedLine Citation:
|
PMID: 20186240 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: To determine whether use of cardiovascular medications by a sample of mid-life and older women is consistent with New Zealand cardiovascular risk guidelines. METHOD: Retrospective analysis of risk factor data collected during the Women's Lifestyle Study involving 1089 40-74 year old women. Outcome measures included: 5-year cardiovascular (CVD) risk score calculated using the adjusted Framingham equation and self-reported use of cardiovascular medications. RESULTS: Seven percent (76/1089) of women had established CVD, and a further 3% (33/1089) had a risk score greater than 15% (high risk). Of the 109 women at high risk (risk score = or >15% or established CVD); 36% (39/109) were taking aspirin, 55% (60/109) were taking blood pressure-lowering medication, 45% (49/109) were taking lipid-lowering medications and 17% (19/109) were taking all three medications. Triple therapy was being taken by 12% of women (4/33) for primary prevention (5-year risk score = or >15%) and only 19.7% of women for secondary prevention (15/76). CONCLUSION: These results suggest that women at high-risk are not receiving cardiovascular medications as recommended by the guidelines, reflecting a 'treatment gap.' Modifiable barriers to the management of women at risk for CVD need to be identified and addressed to reduce cardiovascular morbidity and mortality among women. |
| | |
Authors:
|
Olivia Bupha-Intr; Sally B Rose; Beverley A Lawton; C Raina Elley; Anthony C Dowell |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-02-19 |
Journal Detail:
|
Title: The New Zealand medical journal Volume: 123 ISSN: 1175-8716 ISO Abbreviation: N. Z. Med. J. Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-02-26 Completed Date: 2010-04-06 Revised Date: 2010-10-22 |
Medline Journal Info:
|
Nlm Unique ID: 0401067 Medline TA: N Z Med J Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 26-36 Citation Subset: IM |
Affiliation:
|
Department of Primary Health Care and General Practice, University of Otago, Wellington, New Zealand. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antihypertensive Agents / therapeutic use Antilipemic Agents / therapeutic use Aspirin / therapeutic use Cardiovascular Diseases / epidemiology, prevention & control* Drug Therapy, Combination Ethnic Groups Female Guideline Adherence* Humans Middle Aged New Zealand / epidemiology Platelet Aggregation Inhibitors / therapeutic use Practice Guidelines as Topic* Primary Prevention Randomized Controlled Trials as Topic Retrospective Studies Risk Assessment* Risk Factors Secondary Prevention |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Antilipemic Agents; 0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Door to balloon times: streamlining admission for primary percutaneous coronary intervention.
Next Document: A retrospective review of the use of thromboprophylaxis in patients who subsequently developed a ven...